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ABSTRACT
Background. Chronic kidney disease (CKD) represents an in-
creasing health burden. We present the population-based
prevalence of CKD and compare the CKD Epidemiology
collaboration (CKD-EPI) and modiﬁcation of diet in renal
disease (MDRD) equations to estimate the glomerular ﬁl-
tration rate, using the revised CKD classiﬁcation with three
albuminuria classes. We also explore factors associated with
CKD.
Methods. The Swiss population-based, cross-sectional CoLaus
study conducted in Lausanne (2003–2006) included 2810 men
and 3111 women aged 35–75. CKD prevalence was assessed
using CKD-EPI and MDRD equations and albuminuria
estimated by the albumin-to-creatinine ratio in spot morning
urine. Multivariate logistic regression was used to analyse
determinants of CKD.
Results. Prevalence [95% conﬁdence interval (CI)] of all stages
CKD was 10.0% (9.2–10.8%) with CKD-EPI and 13.8%
(12.9–14.6%) with MDRD. Using the revised CKD classiﬁ-
cation, the prevalence of low-, medium-, high- and very high-
risk groups was 90.0, 8.46, 1.18 and 0.35% with CKD-EPI,
respectively. With MDRD, the corresponding values were
86.24, 11.86, 1.55 and 0.35%. Using the revised classiﬁcation,
CKD-EPI systematically reclassiﬁed people in a lower risk cat-
egory than MDRD. Age and obesity were more strongly
associated with CKD in men [odds ratio (95% CI): 2.23(1.95;
2.56) per 10 years and 3.05(2.08;4.47), respectively] than in
women [1.46 (1.29; 1.65) and 1.78 (1.30;2.44), respectively].
Hypertension, type 2 diabetes, serum homocysteine and uric
acid were positively independently associated with CKD in
men and women.
Conclusions. One in 10 adults suffers from CKD in the popu-
lation of Lausanne. CKD-EPI systematically reclassiﬁes people
in a lower CKD risk category than MDRD. Serum homocysteine
and uric acid levels are associated with CKD independently of
classical risk factors such as age, hypertension and diabetes.
INTRODUCTION
Chronic kidney disease (CKD) prevalence is increasing world-
wide and the prevalence of end-stage renal disease (ESRD) is
expected to rise by 44% from 2000 to 2015 [1]. CKD
represents a signiﬁcant public health problem because of the
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high associated morbidity and mortality, mainly attributable
to elevated cardiovascular risk [2, 3].
A National Kidney Foundation position statement supports
early detection of CKD in asymptomatic individuals at in-
creased risk [4]. Screening for CKD is cost-effective in dia-
betics and hypertensive patients or in the general population
after age 50 [5, 6]. The identiﬁcation of CKD has been facili-
tated by the implementation of new equations to estimate the
glomerular ﬁltration rate (eGFR) and by the National Kidney
Foundation Kidney Disease Outcomes Quality Initiative
(NKF-KDOQI) ﬁve-stage classiﬁcation mainly based on eGFR
levels [7].
The simpliﬁed four-variable modiﬁcation of diet in renal
disease (MDRD) equation is the most commonly used in
clinical practice [8]. However, it was developed in non-diabetic
CKD patients (mean age 51 years) [9] and has not been
validated for eGFR > 60 mL/min/1.73 m2 [10]. An alternative
equation [CKD-Epidemiology collaboration (EPI)] was devel-
oped and validated to reduce the rate of false-positive diagno-
sis of CKD stage 3 [11]. CKD-EPI has proven to be more
accurate than MDRD to estimate eGFR in patients with
normal renal function [12] and to predict ESRD, cardiovas-
cular and all-cause mortality [13]. Recently, a revised classiﬁ-
cation of CKD has been proposed by the Kidney Disease:
Improving Global Outcomes (KDIGO) group. This new
classiﬁcation was developed to reﬂect patient prognosis and
includes albuminuria as there is compelling evidence for its
prognostic value [14–16].
So far, few large-scale population-based studies estimated
the prevalence of CKD comparing CKD-EPI with MDRD
[13, 17–22] and very few used the revised classiﬁcation. The
aim of this study was to assess the prevalence of CKD in the
general population according to the revised classiﬁcation to
compare the MDRD and CKD-EPI equations and to explore
determinants of CKD.
SUBJECTS AND METHODS
Participants
The data from the population-based CoLaus study were
analysed for this study. Between 2003 and 2006, 6184 Cauca-
sian participants aged 35–75 were recruited in Lausanne,
Switzerland. Details on participant selection, assessment
process and clinical data measurements have been described
previously [23]. Brieﬂy, recruitment took place in the city of
Lausanne in Switzerland, a town of 117 161 inhabitants. The
complete list of the Lausanne inhabitants aged 35–75
(n = 56 694 in 2003) was provided by the population register.
A simple, non-stratiﬁed random selection of 35% of the source
population was drawn and contacted by letter. Exclusion
criteria for this study were to be of non-Caucasian descent and
not to be able to provide a written informed consent. The par-
ticipation rate from the randomly selected population was
41%. The study was approved by the local ethical committee
and participants signed written informed consent.
Questionnaire data and clinical measurements
Trained health professionals used standardized question-
naires on socio-demographic characteristics and lifestyle
factors, such as tobacco and alcohol consumption as well as
treatment. Education was split into <9 versus ≥9 years of
school. Physical activity was considered as present if partici-
pants reported to be physically active during at least 20 min
once a week. For the purpose of the present analyses, smokers
were deﬁned as current smokers and non-smokers as never or
ex-smokers. Alcohol consumption was considered as present if
participants reported to drink alcohol on a daily basis. Meno-
pausal status, hormone replacement therapy and oral contra-
ceptive use were assessed via standardized questionnaire. The
body mass index (BMI) was deﬁned as weight in kilograms
divided by height in meters squared (kg/m2) and categorized
into normal (<25 kg/m2), overweight (25≤ BMI < 30 kg/m2)
and obesity (BMI≥ 30 kg/m2). Blood pressure (BP) was
measured three times on the left arm in the sitting position
using a clinically validated automatic oscillometric device [24].
The mean of the last two measures was used to deﬁne hyper-
tension status. Hypertension was deﬁned as a mean systolic BP
≥140 mmHg and/or a diastolic BP ≥90 mmHg and/or the
presence of antihypertensive drug treatment. Diabetes was
deﬁned as a fasting blood glucose ≥7 mmol/L [25] and/or the
presence of any antidiabetic drug (including insulin).
Laboratory data
Blood was drawn in all participants after an overnight fast.
Clinical chemistry assays were performed by CHUV Clinical
Laboratory on fresh blood samples. Serum and urine creati-
nine were measured using the IDMS-traceable Jaffe kinetic
compensated method (Roche Diagnostics, Switzerland,
maximum intra- and inter-batch CV: 2.9–0.7%). A single spot
urine sample was taken randomly in the morning to assess
albuminuria. A quantitative immunonephelometry method
was used to quantify albuminuria. Creatinine and albumin
were measured to calculate the albumin-to-creatinine ratio
(ACR). Uric acid was measured using uricase-PAP (inter- and
intra-batch CV: 1.0–0.5%), triglycerides using GPO-PAP
(inter- and intra-batch CV: 2.9–1.5%), cholesterol using
CHOD-PAP (inter- and intra-batch CV: 1.7–1.6%), homocys-
teine using high-pressure liquid chromatography following
ammonium 7-ﬂuorobenzo-2-oxa-1, 3-diazole -4-sulphonate
(SBD-F) derivatization (inter- and intra-batch CV: 3.1–2.9%).
CKD deﬁnition
GFR was estimated using the simpliﬁed MDRD [8] and the
CKD-EPI equations [11]. Given that the CKD-EPI equation
more accurately predicts the risk of mortality and ESRD than
the MDRD equation [26], CKD-EPI was considered as the
gold standard in this study. The simpliﬁed MDRD equation
adapted for IDMS-traceable serum creatinine was calculated
as follows: GFR (mL/min/1.73 m2) = 175 × (SCr)−1.154 ×
(Age)−0.203 × (0.742 if female), where SCr is serum creatinine
concentration in mg/dL and age is in years [8]. Albuminuria
was deﬁned as present whenever the ACR was above 30 mg/g,
including both micro-albuminuria (ACR 30–299 mg/g) and
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macro-albuminuria (ACR≥ 300 mg/g) [27]. CKD was deﬁned
according to K/DOQI guidelines as eGFR < 60 mL/min/1.73
m2 (stages 3–5) or the presence of albuminuria when eGFR
was greater than 60 mL/min/1.73 m2 (stages 1 and 2).
Throughout the manuscript, the term ‘CKD’ will be used for
all stages (1–5).
The distribution of CKD stages was assessed according to
the revised classiﬁcation as proposed by KDIGO, which in-
cludes three levels of albuminuria using the ACR (A1≤ 10 and
10–29 mg/g; A2 = 30–299 mg/g; A3 = 300–1999 and ≥2000
mg/g) and ﬁve stages of eGFR (G1–G5) [16]. This revised
classiﬁcation allows stratifying people into four risk categories:
low, medium, high and very high risk. Medium, high and very
high risk categories correspond to the traditional K/DOQI
CKD stages 1–5. Because of low numbers, we combined the
revised high and very high categories in all analyses. The
prevalence of CKD according to the revised classiﬁcation was
calculated using the MDRD and CKD-EPI equations.
Statistical analysis
Statistical analyses were conducted using STATA 12.0
(StataCorp, College Station, TX, USA). Quantitative variables
were expressed as the mean ± SD or median and interquartile
range, and categorical ones as the percentage of participants.
We compared continuous and categorical variables in men
and women using the t-test and chi-square tests, median tests
or Fisher’s exact tests whenever appropriate (i.e. expected
value in any cell lower than 5).
We compared the low-, medium- and high-risk CKD
categories between MDRD and CKD-EPI and calculated re-
classiﬁcation percentages. We compared the prevalences of
medium- and high-risk categories by hypertension, diabetes
and BMI strata using a chi-square test. We used a non-
parametric test for trend to compare the low- versus combined
medium- and high-risk revised CKD categories across age and
BMI strata.
Participant characteristics are presented separately for men
and women as all variables except total cholesterol were sig-
niﬁcantly different (P < 0.001). For this reason, we also system-
atically explored all two-way interactions with sex for their
association with the risk of CKD. We found signiﬁcant
(P < 0.05) sex by age, sex by BMI categories (tested using a
likelihood ratio test) and therefore decided to conduct separate
etiological models in men and in women.
We used multiple logistic regressions to explore determi-
nants of CKD. We ﬁrst tested each covariate of interest separ-
ately for its association with CKD in the crude analysis
(unadjusted model 1). For all covariates in model 1, we then
explored the age-adjusted associations (model 2). We then sys-
tematically checked the association of each exposure of interest
one by one with variables signiﬁcantly associated with CKD in
the model 1 to detect potential confounders. We ﬁnally built a
model (ﬁnal model 3) for each exposure factor of interest ad-
justing for their confounders. Covariates that could lie in the
causal pathway (i.e. variable that could be a consequence of
the factor of interest and inﬂuence the outcome) were not in-
cluded in the model. For example, hypertension, diabetes, tri-
glycerides and uric acid could be in the causal pathway of the
BMI-CKD association and were excluded from the ﬁnal
model. We also explored whether covariates of interest (e.g.
smoking, alcohol consumption, physical activity etc.) not sig-
niﬁcantly associated with CKD in univariate analyses con-
founded the association of the other covariates with CKD, but
that was not the case. We additionally explored the effects of
adding as covariates to models three factors that did not
qualify as confounders in our data set but may be argued to
represent confounders based on previously published data: no
signiﬁcant changes were observed. We expressed associations
as odds ratio (OR) and 95% CIs.
RESULTS
Participant characteristics
Overall, 263 participants had missing data on renal func-
tion, serum homocysteine, serum uric acid, alcohol, smoking
or on menopausal status and were excluded from the present
analyses. We included 5921 subjects (95.7%) with complete
information on renal function as assessed by creatinine and
albuminuria measurements: 2810 men and 3111 women.
Participants’ characteristics according to sex are displayed in
Table 1. Men were younger than women but had a higher
BMI, higher eGFR (CKD-EPI and MDRD) and higher trigly-
cerides, serum uric acid and homocysteine levels. Men also
reported higher alcohol intake, higher physical activity and
were more educated. Men had the higher prevalence of cardio-
vascular risk factors such as smoking, diabetes, hypertension
and albuminuria.
GFR distribution: comparison between MDRD
and CKD-EPI equations
Scatterplots of eGFR versus serum creatinine as well as se-
lected percentiles for eGFR in the adult general population are
shown in Figure 1, separately for men and women, according
to MDRD and CKD-EPI equations. Compared with the CKD-
EPI equation, MDRD underestimated eGFR in all presented
percentiles in men and women. The median value for eGFR
(CKD-EPI) was higher than for eGFR (MDRD) in men
(89 versus 81 mL/min/1.73 m2, P < 0.001) and women
(84 versus 75 mL/min/1.73 m2, P < 0.001).
Revised CKD classiﬁcation using the MDRD
and CKD-EPI equations
Table 2 shows the percentage of participants in each
category of the revised classiﬁcation for CKD using both the
CKD-EPI and MDRD equations. For CKD-EPI, the preva-
lence in the low-, medium-, high- and very high-risk cat-
egories was 90.0, 8.46, 1.18 and 0.35%, respectively. The
corresponding values for MDRD were .86.24, 11.86, 1.55 and
0.35%. The prevalence of CKD in our sample was 10.0% [95%
conﬁdence interval (CI): 9.2–10.8%] for CKD-EPI and 13.8%
(95% CI: 12.9–14.6%) for MDRD.
We compared CKD-EPI and MDRD across the low-,
medium- and high-risk categories based on the new CKD
classiﬁcation (Supplementary Table S1). We calculated the re-
classiﬁcation that occurred when using the CKD-EPI instead
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of the MDRD equation. Compared with MDRD, CKD-EPI
reclassiﬁed 31.8% from medium to low risk and 19.5% from
high to medium risk overall. The corresponding percentages
were 16.1 and 12.7% in men and 41.4 and 25.9% in women.
All reclassiﬁcations were in the direction of a lower risk
category.
Factors associated with CKD
The unadjusted prevalence of CKD by age and sex are
depicted in Figure 2. Prevalence increased with age mainly in
subjects aged ≥55 years, being over 25% after 65 years old.
Prevalence of CKD was higher in women compared with men
before 55 years old but higher in men over 55 years old.
The unadjusted prevalences of combined medium- and
high-risk CKD categories were signiﬁcantly higher in the pres-
ence of diabetes (28.6 versus 8.7% in the absence, P < 0.001) or
hypertension (17.4 versus 5.9% in the absence, P < 0.001) as
presented in Supplementary Figure S1. Results were similar
in men and women. There was a signiﬁcant positive trend in
the prevalence of combined medium- and high-risk CKD
categories across BMI categories (7.1% in normal weight
people, 10.8% in overweight people and 17.2% in obese
people, P for trend < 0.001) overall. Signiﬁcant positive trends
across BMI categories were also observed when men and
women were analysed separately.
In the multivariate analysis, older age, overweight, obesity,
hypertension, diabetes as well as serum triglyceride, uric acid
and homocysteine levels were independent determinants of
CKD in men (Table 3). However, the signiﬁcant association
of triglycerides with CKD was only present when age was in-
cluded as a covariate in the model. In contrast, overweight and
serum triglycerides were not signiﬁcantly associated with CKD
in women, while older age, hypertension, diabetes, serum uric
acid and homocysteine levels were (Table 4). Obesity was only
Table 1. Participants’ characteristics by sex (n = 5921)
Covariate Men (n = 2810) Women (n = 3111) P-value
Age (years) 52.5 (10.7) 53.5 (10.7) <0.001
Menopause (%) — 56.1
More than basic education (>9 years) (%) 82.8 76.2 <0.001
Physical activity (at least 1/week) (%) 10.7 7.52 <0.001
Smoking (%) 29.1 24.9 <0.001
Alcohol consumption (%) 36.1 15.6 <0.001
ACE inhibitor (%) 6.16 4.18 <0.001
ARBs (%) 8.29 6.46 0.007
Lipid-lowering drug (%) 14.3 9.16 <0.001
BMI (Kg/m2) 26.6 (4.0) 25.1 (4.8) <0.001
Normal weight (%) 37.4 57.3
Overweight (%) 45.6 28.4
Obesity (%) 17.0 14.3 <0.001
Hypertension (%) 42.1 30.1 <0.001
Diabetes (%) 9.32 4.05 <0.001
Serum creatinine (μmol/L) 88.6 (23.3) 72.1 (11.7) <0.001
eGFR (CKD-EPI) (mL/min/1.73 m2) 87.7 (15.0) 84.0 (15.0) <0.001
eGFR (MDRD) (mL/min/1.73 m2) 81.6 (15.7) 75.9 (14.2) <0.001
Albuminuria (ACR≥ 30 mg/g) (%) 9.50 5.24 <0.001
Total cholesterol (mmol/L) [median (IQR)] 5.5 (4.9; 6.2) 5.5 (4.9; 6.3) 0.41
Serum triglycerides (mmol/L) [median (IQR)] 1.3 (0.9; 1.9) 1.0 (0.7; 1.4) <0.001
Serum uric acid (μmol/L) [median (IQR)] 355 (308; 407) 262 (224; 309) <0.001
Serum homocysteine (μmol/L) [median (IQR)] 10.4 (8.8; 12.6) 8.8 (7.3; 10.6) <0.001
Data are the means (SD) unless otherwise speciﬁed. eGFR, estimated glomerular ﬁltration rate; ACR, albumin-to-creatinine ratio,
IQR, interquartile range.
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found to be associated with CKD in women when serum uric
acid was excluded from the model (possible causal pathway).
Menopausal status was still associated with the substantially
lower risk of CKD in women [OR (95% CI): 0.47 (0.30–0.73)],
once adjusted for all confounders including age. Hypertension
was associated with an ∼50% higher risk of CKD, and diabetes
with a 2-fold higher risk of CKD, in both genders.
DISCUSSION
We report, for the ﬁrst time in Switzerland, the prevalence of
CKD using both eGFR and albuminuria in a population-based
sample aged 35–75 years. One in 10 adults suffers from CKD
in the city of Lausanne. When using the CKD-EPI equation to
estimate, the prevalence in the low-, medium-, high- and very
high-risk categories of the revised KDIGO CKD classiﬁcation
[16] was 90.0, 8.46, 1.18 and 0.35%, respectively. These data
add to the few population-based estimates of the newly pro-
posed KDIGO CKD risk categories in Europe. A large body of
literature conﬁrms that detecting CKD with albuminuria and
eGFR is cost effective and better associated with adverse out-
comes such as all-cause and cardiovascular mortality and
ESRD [14, 15, 28–30]. Those ﬁndings justify the use of both
the eGFR equation and albuminuria to determine CKD preva-
lence. In this study, we found lower rates in G1 stages but
F IGURE 1 : Estimated GFR levels versus serum creatinine levels by sex according to MDRD (a) and CKD-EPI (b) equations. MDRD, modiﬁ-
cation of diet in renal disease equation; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration equation. Percentiles 5, 25, 50, 75 and
95 for eGFR in men and women are provided as well.
Table 2. Prevalence of CKD stages according to the new proposed KDIGO classiﬁcation [16], based
on eGFR calculated with the CKD-EPI or [MDRD] equation
eGFR stages (mL/
min/1.73 m2)
Albuminuria stagesa
A1 A2 A3
<10 [10–30[ [30–300[ ≥300 All
G1 ≥105 8.17 [3.19] 1.77 [1.00] 0.59 [0.32] 0.07 [0.07] 10.61 [4.58]
[90–105[ 23.54 [11.81] 4.95 [2.74] 1.49 [1.01] 0.19 [0.07] 30.16 [15.62]
G2 [75–90[ 28.44 [29.39] 4.81 [5.35] 1.82 [1.87] 0.08 [0.15] 35.16 [36.77]
[60–75[ 14.85 [27.73] 3.46 [5.03] 1.22 [1.69] 0.08 [0.14] 19.61 [34.59]
G3a [45–60[ 2.35 [5.12] 1.00 [1.84] 0.47 [0.69] 0.05 [0.03] 3.87 [7.68]
G3b [30–45[ 0.24 [0.35] 0.05 [0.08] 0.14 [0.14] 0.02 [0.03] 0.44 [0.61]
G4 [15–30[ 0.03 [0.03] 0.02 [0.02] 0.02 [0.02] 0.03 [0.03] 0.10 [0.10]
G5 <15 0.00 [0.00] 0.00 [0.00] 0.02 [0.02] 0.03 [0.03] 0.05 [0.05]
All 77.62 [77.62] 16.06 [16.06] 5.76 [5.76] 0.56 [0.56] 100 [100]
Low risk (very light grey), medium risk (light grey), high risk (medium grey), very high risk (dark grey). For both CKD-EPI and MDRD,
three participants (i.e. 0.05%) belonging to the G5 category have been included in the very high-risk category.
aStages of the ACR in mg/g. n = 5921.
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higher in G2 and G3a than those reported in the USA in
NHANES III [16].
The SAPALDIA study previously reported CKD prevalence
deﬁned as an eGFR < 60 mL/min/1.73 m2 in a large Swiss
population-based sample but used neither KDOQI stages nor
albuminuria in their deﬁnition [31]. CKD prevalence strongly
varies depending on the inclusion, or omission, of albuminur-
ia in the deﬁnition, the studied population and the country.
When CKD was solely deﬁned by an eGFR < 60 mL/min/1.73
m2, the overall prevalence in population-based studies varied
between 1.5 and 43.3% [32, 33]. Differences in population
sampling, age restriction, number of creatinine samples to
deﬁne CKD (one versus more) or equation used to estimate
eGFR (Cockroft-Gault, MDRD or CKD-EPI) explain some of
the observed variability. The different assays used to measure
creatinine as well as different standardization methods may
also account for some of the observed heterogeneity: although
most studies used Jaffe assays, instead of enzymatic ones, those
could be compensated or uncompensated, IDMS traceable or
not. Studies including elderly participants (>75 years old),
patients at high cardiovascular risk, or those using uncompen-
sated Jaffe creatinine assays reported higher CKD prevalences.
Studies that combined eGFR < 60 mL/min/1.73 m2 and protei-
nuria to deﬁne CKD reported a prevalence ranging between 8
and 13.2% [34–41]. Although few population-based studies in
Europe have assessed CKD including proteinuria, the preva-
lence seems to be lower in northern (8–10.2%) [34, 36] than in
southern countries (12.7–13.2%) [39, 40]. The overall preva-
lence of CKD in our study (MDRD: 13.8% (95% CI: 12.9–
14.6%) was quite similar to the values reported in Southern
European countries, and in the USA [NHANES 1999–2004:
13.1% (12.0–14.1%)] [35].
Most of the previously mentioned studies used MDRD
equations. In our study, CKD prevalence was lower using
the CKD-EPI than the MDRD equation: 10.0% (95% CI:
9.2–10.8%) instead of 13.8% (95% CI: 12.9–14.6%). CKD-EPI
reclassiﬁed 8.2% of people and this was systematically in the
direction of a lower-risk category than MDRD. Data on CKD
prevalence deﬁned using the CKD-EPI equation are scarce in
Europe and only few population-based studies compared
CKD-EPI with MDRD equation [13, 18, 20–22]. In those
studies, CKD-EPI similarly reclassiﬁed individuals, from CKD
stages 2 and 3 to a higher eGFR category.
In agreement with previous reports, we found a higher
prevalence of CKD in diabetic (30%) and hypertensive (18%)
participants [30, 42]. Both hypertension and diabetes were
associated with the increased risk of CKD independently of
other determinants in a similar way in men and women.
In contrast, the associations of age and obesity with CKD
signiﬁcantly differed in men and in women in our study, with
a stronger association in men. In both human and animal
experiments, the precise underlying causes of sex difference in
CKD are unclear and may include diet, kidney size, glomerular
haemodynamics and sex hormones [43–45].
We found overweight and obesity as well as triglyceride
levels to be associated with CKD in men. In women, only
obesity was associated with CKD but the association was
smaller than in men. Additionally, in women, this association
disappeared when adjusting for serum uric acid potentially
due to an over-adjustment for adiposity [46]. In longitudinal
studies, obesity was often reported as an independent risk
factor for incident CKD, without any mention of sex differ-
ences [47, 48]. In a meta-analysis, obesity was a signiﬁcant in-
dependent risk factor for ESRD with a stronger association in
men for severe obesity [49]. However, in another meta-analysis,
including not only CKD but also ESRD, kidney stones and
kidney cancer studies, obesity was a stronger determinant of
kidney disease in women than men [50].
Hyperhomocysteinaemia has been previously shown to be
a determinant of CKD and albuminuria in the general popu-
lation [51, 52]. This relation has been conﬁrmed and already
discussed in the CoLaus cohort in another manuscript that
F IGURE 2 : Prevalence of medium- and high-risk categories using the revised CKD classiﬁcation by 10-year age groups and by sex. P-values
are from a non-parametric test for trend (nptrend in Stata 12.0) comparing the trend in combined medium- and high-risk categories versus
low-risk category across age groups.
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focused on albuminuria [53]. Similarly, several cross-sectional
and longitudinal analyses demonstrated an association
between serum uric acid and CKD in the general population
[38, 54–58]. Homocysteine might lead to endothelial injury
through generation of hydrogen peroxide and a decrease in
NO [59] and, although mechanisms are not yet clear, uric acid
also seems to contribute to endothelial dysfunction through
impaired NO production and release [60]. Our results suggest
that oxidative stress could be an important determinant of
CKD in the general Swiss adult population.
Our study has some limitations. First, we included partici-
pants from a single city, which might limit generalizing the
ﬁndings to the whole country. Second, only Caucasians were
included and results might be different in an African or Asian
Table 3. Factors associated with CKD in men (n = 2810)
Model 1
unadjusted
OR (95% CI)
Model 2: age-
adjusted OR
(95% CI)
Confounder X Possible
causal
pathway
Final model 3:
adjusted for X OR
(95% CI)
Final
model
P-value
Age (per 10-year
increase)
2.39
(2.10;2.73)
— Hn OH BMI HT
DM Ura
2.23 (1.95; 2.56) <0.001
BMI < 25 kg/m2 1 1 Age HT DM
Tg Ura
1
BMI 25–30 kg/m2 2.56
(1.83;3.57)
2.02
(1.44;2.85)
2.02 (1.44; 2.85) <0.001
BMI ≥30 kg/m2 4.26
(2.94;6.16)
3.05
(2.08;4.47)
3.05 (2.08; 4.47) <0.001
Hypertension
(presence versus
absence)
4.49
(3.40;5.93)
2.48
(1.84;3.35)
All — 1.66 (1.21; 2.28) 0.002
Type 2 diabetes
(presence versus
absence)
4.61
(3.40;6.24)
2.99
(2.18;4.11)
Age BMI HT
Ura Hn OH
Tg 2.41 (1.70; 3.41) <0.001
Triglycerides
(per 1 mmol/L
increase)a
1.15
(1.08;1.23)
1.22
(1.13;1.30)
All — 1.10 (1.02; 1.89) 0.019
Uric acid
(per 10 μmol/L
increase)a
1.08
(1.06;1.09)
1.07
(1.05;1.08)
Age Tg Hn
BMI OH
HT DM 1.04 (1.03; 1.06) <0.001
Homocysteine
(per 1 μmol/L
increase)a
1.09
(1.07;1.11)
1.07
(1.05;1.09)
Age HT DM
Tg Ura OH
— 1.05 (1.03–1.08) <0.001
Alcohol
consumption
(yes versus no)
1.55
(1.21;1.99)
1.15
(0.89;1.49)
Age HT DM
Hn
Tg Ura 1.03 (0.78; 1.4) 0.80
Education level
(high versus low)
0.97
(0.70;1.35)
0.95
(0.68; 1.34)
— —
Physical activity
(regular versus
not)
0.89
(0.58;1.34)
1.25
(0.81; 1.93)
— —
Smoking (current
versus not)
0.89
(0.67;1.17)
1.10
(0.82; 1.47)
— —
Total cholesterol
(per 1 mmol/L)
0.93
(0.83;1.05)
0.95
(0.84; 1.08)
— —
CKD was deﬁned as the presence of stages 1–5 CKD using the CKD-EPI equation. In a model including both men and women, there was a
signiﬁcant age-by-sex interaction (P < 0.001) and age by BMI categories interaction (P = 0.006), so that separate models were built for men
and women. BMI, body mass index; HT, hypertension; DM, type 2 diabetes mellitus; Tg, triglycerides; Ura, uric acid; Hn, homocystein;
OH, alcohol.
aSerum values.
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population. Additionally, CKD classiﬁcation was based on a
single measurement of serum creatinine and the ACR, as in
most population-based studies. Third, a compensated IDMS-
traceable Jaffe method was used and not an enzymatic
method. The small bias due to the method is minimized by
the use of the appropriate calibrated MDRD equation [61].
Most previous studies reporting CKD prevalences have also
used a compensated Jaffe assay (calibrated or not) and not an
Table 4. Factors associated with CKD in women (n = 3111)
Model 1:
unadjusted
OR (95%CI)
Model 2: age-
adjusted OR
(95%CI)
Confounder X Possible
causal
pathway
Final model 3:
adjusted for X
OR (95% CI)
Final
model
P-value
Age (per 10-year
increase)
1.73
(1.54;1.94)
— Hn S Mp BMI
HT DM
Tg Ct Ura
1.46 (1.29; 1.65) <0.001
Menopause (yes
versus no)
2.11
(1.62;2.72)
0.56
(0.36;0.85)
All — 0.47 (0.30–0.73) 0.001
BMI <25 kg/m2 1 1 Age Mp Hn S HT DM
Tg Ura Ct
1
BMI 25–30 kg/m2 1.19
(0.90;1.57)
0.98
(0.74;1.31)
1.01 (0.76; 1.35) 0.95
BMI ≥30 kg/m2 2.20
(1.63;2.97)
1.84
(1.35;2.50)
1.78 (1.30; 2.44) <0.001
Hypertension
(presence versus
absence)
2.78
(2.20;3.53)
1.91
(1.47;2.47)
All — 1.56 (1.17; 2.07) <0.001
Type 2 diabetes
(presence versus
absence)
3.93
(2.62;5.89)
2.91
(1.92;4.41)
Age Mp BMI
HT Ura Hn
Tg 2.10 (1.32; 3.32) <0.001
Triglycerides (per
1 mmol/L
increase)a
1.63
(1.39;1.90)
1.41
(1.20;1.67)
Age Mp BMI
HT DM Ura
Hn
Ct 1.13 (0.92; 1.37) 0.25
Uric acid (per
10 μmol/L
increase)a
1.09
(1.07;1.11)
1.07
(1.05;1.09)
Age Mp BMI
Tg Hn Ct
HT DM 1.06 (1.04; 1.08) <0.001
Homocysteine
(per 1 μmol/L
increase)a
1.17
(1.13;1.21)
1.13
(1.09;1.17)
All except
smoking
— 1.10 (1.06; 1.14) <0.001
Total cholesterol
(per 1 mmol/L)
1.26
(1.13;1.41)
1.05
(0.93;1.19)
Age Mp HT
Ura Hn BMI
Tg 1.04 (0.92; 1.18) 0.67
Smoking (current
versus not)
0.69
(0.52;0.93)
0.82
(0.60;1.10)
Age Mp BMI
HT Ura
— 0.92 (0.67; 1.25) 0.58
Education level
(high versus low)
0.86
(0.66;1.13)
1.01 (0.77;
1.33)
— — —
Physical activity
(regular versus
not)
0.93
(0.59;1.46)
1.24 (0.78;
1.97)
— — —
Alcohol
consumption (yes
versus no)
1.30
(0.96;1.76)
0.99 (0.72;
1.35)
— — —
Mp, menopause; BMI, body mass index; HT, hypertension; DM, type 2 diabetes mellitus; Tg, triglycerides; Ura, uric acid; Hn, homocystein;
Ct, total cholesterol; S, smoking.
CKD was deﬁned as the presence of stages 1–5 CKD using the CKD-EPI equation.
aSerum values.
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enzymatic one. Additionally, the participation rate in the
CoLaus study from the original randomly selected sample was
41%. Although the sex distribution of participants and non-
participants was similar, participants were under-represented
in older age groups compared with non-participants
(P < 0.001), which could underestimate CKD prevalence. Fur-
thermore, we cannot exclude a healthy participant bias, which
would lead to further underestimate CKD prevalence in this
study. In contrast, we expect people with ESRD not to take
part in such population-based study. Altogether, we expect the
true underlying CKD prevalence to be likely higher than 10%.
In this population-based sample, the numbers of participants
in the medium-, high- and very high-risk categories (accord-
ing to the revised KDIGO classiﬁcation) were too low for us to
separately explore their correlates. Finally, the cross-sectional
nature of the study limits causal inferences. For instance, some
of the factors (e.g. hypertension) that we found to be associ-
ated with CKD could either precede or follow the appearance
of CKD (unclear temporal sequence). A longitudinal study
would be needed to assess whether baseline characteristics are
associated with incident CKD.
In conclusion, one in 10 adults suffers from CKD in the
population of Lausanne. Age and obesity are more strongly
associated with CKD in men than in women, whereas type 2
diabetes, hypertension, serum homocysteine and uric acid
levels are independently positively associated with the risk of
CKD in both genders.
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ABSTRACT
Background. There is a lack of high-quality evidence that
advocates the use of corticosteroids for IgA nephropathy
(IgAN) with minimal change-like lesions (also called IgAN
with minimal change disease, MCD-IgAN).
Methods. Twenty-seven biopsy-proven adult MCD-IgAN
patients were enrolled. Daily single dose of 1 mg/kg
(maximum 60 mg/day) prednisone was given until complete
remission (CR), followed by gradually decreasing dosage. The
clinical data were collected from baseline up to 12 weeks of
treatment (Certiﬁcation No. 2011NLY-006, Clinical trials gov
ID. NCT01451710).
Results. The patient cohort consisted of 15 males and 12
females. The mean age of the patients was 29.2 ± 10.8 years
(range 18–60 years) at the time when they were subject to
renal biopsy. All patients had hypoalbuminaemia (23.7 ± 4.13
g/L) and heavy proteinuria (>3.5 g/24 h). Cumulative CR
(proteinuria < 0.4 g/24 h) rates were 3.70, 48.1, 92.6 and 100%
after 1, 2, 4 and 8 weeks of treatment, respectively. Two cases
relapsed after CR, one at 6 weeks of treatment, likely due to
O
R
IG
IN
A
L
A
R
T
IC
L
E
© The Author 2013. Published by Oxford University Press on
behalf of ERA-EDTA. All rights reserved.
2339
